According to the Dow Jones Newswires (11/10, Loftus) reported that Johnson & Johnson disclosed Wednesday that it is in talks with the government to settle an investigation into whether the company improperly marketed the antipsychotic Risperdal.
NATIONAL – Johnson and Johnson lost a $257.7 million jury verdict for making misleading claims about the safety of the company’s Risperdal antipsychotic drug. In addition, Johnson and Johnson officials defrauded Medicaid by wrongfully touting Risperdal as superior to competing antipsychotic drugs and minimizing its links to diabetes, said jurors. Tripp Law Firm – Personal Injury Law Relevant Practice Areas